Beauty Health (SKIN) Expected to Announce Earnings on Thursday

Beauty Health (NASDAQ:SKIN) will likely be posting its Q4 2025 results after the market closes on Thursday, March 12th. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $78.0650 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 12, 2026 at 4:30 PM ET.

Beauty Health Trading Down 4.2%

Shares of Beauty Health stock opened at $1.13 on Wednesday. Beauty Health has a fifty-two week low of $0.78 and a fifty-two week high of $2.69. The business’s fifty day moving average is $1.28 and its two-hundred day moving average is $1.53. The company has a quick ratio of 4.07, a current ratio of 4.98 and a debt-to-equity ratio of 5.53. The firm has a market cap of $144.08 million, a PE ratio of -5.14 and a beta of 1.20.

Hedge Funds Weigh In On Beauty Health

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Public Employees Retirement System of Ohio acquired a new stake in Beauty Health in the third quarter valued at approximately $26,000. Atom Investors LP acquired a new position in shares of Beauty Health during the fourth quarter worth $29,000. Franklin Resources Inc. purchased a new position in shares of Beauty Health in the third quarter valued at $31,000. Ieq Capital LLC purchased a new position in shares of Beauty Health in the fourth quarter valued at $33,000. Finally, Zacks Investment Management acquired a new stake in Beauty Health during the 3rd quarter valued at $35,000. Hedge funds and other institutional investors own 93.26% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on SKIN. TD Cowen raised their price target on Beauty Health from $1.50 to $1.65 and gave the stock a “hold” rating in a research note on Wednesday, January 21st. Zacks Research downgraded shares of Beauty Health from a “hold” rating to a “strong sell” rating in a research note on Wednesday, January 21st. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $1.60 target price on shares of Beauty Health in a research report on Wednesday, January 14th. One equities research analyst has rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Beauty Health has an average rating of “Reduce” and a consensus target price of $2.40.

About Beauty Health

Beauty Health Company (NASDAQ: SKIN) is a U.S.-based consumer wellness and beauty enterprise that integrates device-based and product-based offerings across skin, body and hair wellness categories. The company operates a portfolio of established brands that blend professional and at-home solutions, focusing on innovative formulations and technologies to address a range of beauty and self-care needs. Through its proprietary e-commerce platforms and strategic retail partnerships, Beauty Health seeks to deliver premium experiences and tangible results to a global customer base.

Beauty Health’s brand portfolio includes Sol de Janeiro, known for its award-winning Brazilian Bum Bum Cream body care collection; Elemis, a U.K.-originated professional skin care line distributed in spas and skincare clinics; NuFACE and Dermaflash, two at-home beauty device brands specializing in microcurrent facial toning and gentle exfoliation respectively; and Nutrafol, a legal-strength hair wellness supplement clinically designed to support hair growth.